Agonistic CD40 antibody therapy activates PDAC-associated myeloid cells through immune co-stimulatory receptor CD40, inducing both innate and tumor-specific immunity and sensitizing the tumor microenvironment to other immunotherapies5, 6. This evidence concerns the gene CD40 and neoplasm.